LYRA · As filed with the SEC
Lyra Therapeutics income statement, by quarter
The statement as Lyra Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD
| USD | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | — | 25,000 | 183,000 | 183,000 | — | 195,000 | 598,000 | 532,000 |
| Operating expenses: | ||||||||
| Research and development | — | 4,047,000 | 5,110,000 | 4,876,000 | — | 5,902,000 | 13,264,000 | 18,238,000 |
| General and administrative | — | 2,236,000 | 3,501,000 | 3,263,000 | — | 3,931,000 | 5,139,000 | 5,818,000 |
| Impairment of property and equipment | — | 0 | 0 | — | — | 1,900,000 | 1,883,000 | — |
| Impairment of right-of-use assets | — | 0 | 0 | — | — | — | 22,836,000 | — |
| Restructuring and other related charges | — | (21,000) | 398,000 | 885,000 | — | 2,804,000 | 6,450,000 | — |
| Total operating expenses | — | 6,262,000 | 9,009,000 | 9,024,000 | — | 12,637,000 | 49,572,000 | 24,056,000 |
| Loss from operations | — | (6,237,000) | (8,826,000) | (8,841,000) | — | (12,442,000) | (48,974,000) | (23,524,000) |
| Other income: | ||||||||
| Interest income | — | 256,000 | 410,000 | 298,000 | — | 576,000 | 855,000 | 1,086,000 |
| Other Income | — | 0 | 981,000 | — | — | — | — | — |
| Total other income | — | 256,000 | 1,391,000 | 298,000 | — | 576,000 | 855,000 | 1,086,000 |
| Loss before income tax expense | — | (5,981,000) | (7,435,000) | (8,543,000) | — | (11,866,000) | (48,119,000) | (22,438,000) |
| Income tax expense | — | (3,000) | (2,000) | (4,000) | — | (7,000) | (12,000) | (14,000) |
| Net loss | — | (5,984,000) | (7,437,000) | (8,547,000) | — | (11,873,000) | (48,131,000) | (22,452,000) |
| Other comprehensive loss: | ||||||||
| Unrealized holding income (loss) on short-term investments, net of tax | — | 0 | 0 | 0 | — | 24,000 | (29,000) | (8,000) |
| Comprehensive loss | — | (5,984,000) | (7,437,000) | (8,547,000) | — | (11,849,000) | (48,160,000) | (22,460,000) |
| Net loss per share attributable to common stockholders- basic | — | (3.38) | (5.51) | (0.13) | — | (0.18) | (0.74) | (0.35) |
| Net loss per share attributable to common stockholders-diluted | — | (3.38) | (5.51) | (0.13) | — | (0.18) | (0.74) | (0.35) |
| Weighted-average common shares outstanding-basic | — | 1,767,814 | 1,348,630 | 65,757,860 | — | 65,456,735 | 65,459,678 | 64,011,360 |
| Weighted-average common shares outstanding-diluted | — | 1,767,814 | 1,348,630 | 65,757,860 | — | 65,456,735 | 65,459,678 | 64,011,360 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.